These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 39131380)

  • 1. Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models.
    Adams KM; Wendt JR; Wood J; Olson S; Moreno R; Jin Z; Gopalan S; Lang JD
    bioRxiv; 2024 Jul; ():. PubMed ID: 39131380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines.
    Piscazzi A; Condelli V; Crispo F; Coda ARD; Calice G; Bruno G; Venuto S; Tibullo D; Giordano G; Pietrafesa M; Liso A; Landriscina M
    Oncol Lett; 2022 Jun; 23(6):185. PubMed ID: 35527787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
    Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
    Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
    Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
    J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
    Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma.
    Saito R; Kuroda T; Yoshida H; Sudo K; Saito M; Tanabe H; Takano H; Yamada K; Kiyokawa T; Yonemori K; Kato T; Okamoto A; Kohno T
    Jpn J Clin Oncol; 2023 Aug; 53(9):781-790. PubMed ID: 37248674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
    Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
    Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
    Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
    Wang Z; Yang L; Su X; Wu X; Su R
    J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
    J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
    Roering P; Siddiqui A; Heuser VD; Potdar S; Mikkonen P; Oikkonen J; Li Y; Pikkusaari S; Wennerberg K; Hynninen J; Grenman S; Huhtinen K; Auranen A; Carpén O; Kaipio K
    Front Oncol; 2022; 12():954430. PubMed ID: 36081565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.
    Buttitta F; Di Marino P; Felicioni L; Primavera FC; Ferro B; Zampacorta C; Pasciuto MP; Rossetti R; Tudini M; Marchetti A; D'Angelo E
    Pathologica; 2023 Apr; 115(2):107-110. PubMed ID: 37114628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.